Regulatory developments continue to shape pharmaceutical innovation and drug pricing frameworks. FDA leaders from CDER and CBER are scheduled to convene with BIO and PhRMA representatives to discuss plans for reauthorization of the Prescription Drug User Fee Act (PDUFA), aiming to streamline drug review processes. Concurrently, the Trump administration advances finalization of the Medicare Part D Most Favored Nation (MFN) pricing rule, provoking discourse on its implications for market dynamics and access. These dialogues underscore evolving regulatory landscapes impacting biotech and pharma stakeholders.